Cargando…

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

BACKGROUND: The World Health Organisation recommended dolutegravir (DTG)-based antiretroviral therapy (ART) regimens are available but not reimbursed through the public reimbursement system in China. The objective of this analysis was to evaluate the cost-effectiveness of DTG (DTG + TDF/3TC) compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Punekar, Yogesh Suresh, Guo, Na, Tremblay, Gabriel, Piercy, James, Holbrook, Tim, Young, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896323/ https://www.ncbi.nlm.nih.gov/pubmed/31827410 http://dx.doi.org/10.1186/s12962-019-0195-2

Ejemplares similares

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States
por: Butler, Karin, et al.
Publicado: (2021)

Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
por: Nickel, Katharina, et al.
Publicado: (2021)

Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
por: Nickel, Katharina, et al.
Publicado: (2021)

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis
por: Snedecor, Sonya J., et al.
Publicado: (2019)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
por: Nakaharai, Kazuhiko, et al.
Publicado: (2017)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus
por: Hirigo, Agete Tadewos, et al.
Publicado: (2022)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania
por: Mutagonda, Ritah F., et al.
Publicado: (2022)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

1329. Experiences and Emotional Challenges of Antiretroviral Treatment (ART)—Findings from the Positive Perspectives Study
por: De Los Rios, Patricia, et al.
Publicado: (2019)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection
por: Cahn, Pedro, et al.
Publicado: (2022)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
por: Cruciani, Mario, et al.
Publicado: (2019)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Isotopic Radiolabeling of the Antiretroviral Drug [(18)F]Dolutegravir for Pharmacokinetic PET Imaging
por: Tisseraud, Marion, et al.
Publicado: (2022)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2013)

Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy
por: Chen, Guan-Jhou, et al.
Publicado: (2019)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir
por: Campogiani, Laura, et al.
Publicado: (2019)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol
por: Villa, Giovanni, et al.
Publicado: (2022)

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
por: Rudd, Deanne Jackson, et al.
Publicado: (2021)

Contraception use and HIV outcomes among women initiating dolutegravir‐containing antiretroviral therapy in Kenya: a retrospective cohort study
por: Humphrey, John M., et al.
Publicado: (2022)

IMPLEMENTATION AND OUTCOMES OF DOLUTEGRAVIR-BASED FIRST-LINE ANTIRETROVIRAL THERAPY FOR PEOPLE WITH HIV IN SOUTH AFRICA: A RETROSPECTIVE COHORT STUDY
por: Dorward, Jienchi, et al.
Publicado: (2023)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oo4hr6fp0jpu56fm22snnfoqii